EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users

Alice K Schaack, Maxwell B Allamong, Frances Hung, Richard T Barfield, Sarah M Wilson, Tina Watkins, Katherine Link, Mehri S McKellar

AIDS and Behavior · 2025-10 · 29 (10) · 3026-3035

DOI: 10.1007/s10461-025-04749-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS and Behavior, online erschienen am 17.06.2025. Verfasst von Alice K Schaack und 7 weiteren Autor:innen. Beteiligte Einrichtung: Duke School of Medicine, Duke University, Durham, NC, USA. aliceschaack@gmail.com. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Center for AIDS Research, Duke University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) has potential to increase PrEP uptake and adherence. However, most studies investigating opinions about LAI PrEP were done prior to its approval. We administered a cross-sectional electronic survey to clients at an urban PrEP clinic in the U.S. South. Eligible participants were 18 + and had previously taken or been prescribed oral or LAI PrEP. They were asked their opinions on PrEP, barriers to access, perceived HIV risk, and PrEP stigma. Between January and April 2024, 123 people participated. Twenty-two (17.9%) used LAI PrEP, 80 (65.0%) oral PrEP, and 21 (17.1%) were not currently using PrEP. Most participants identified as men (87.8%), and mean age was 38.6 (range 19-78). Participants were 52.8% White, 27.6% Black, and 14.6% Latinx. 56.1% preferred injection versus daily oral pill. Common concerns about PrEP included side effects (n = 48), cost of medication (n = 21), and cost of clinic visits/tests (n = 21). Of those taking oral PrEP, 56.3% reported remaining on oral because LAI was not offered to them and/or they were not aware of it. Perceived HIV risk scores were on average higher for those not currently taking PrEP (not on = 26.8, SD = 6.54; LAI = 22.3, SD = 6.45; oral = 24.2, SD = 6.13). Overall, participants had low to moderate PrEP stigma scores. Despite majority preference for LAI PrEP, patients are frequently unaware of or not offered LAI. Common concerns about PrEP include side effects and costs. These data demonstrate the importance of improving LAI PrEP awareness and accessibility of choice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisHIV InfectionsAnti-HIV AgentsHumansMaleAdultFemaleCross-Sectional StudiesMiddle AgedAdministration, OralYoung AdultAgedInjectionsHealth Knowledge, Attitudes, PracticeDelayed-Action PreparationsSurveys and QuestionnairesMedication AdherenceSocial StigmaUnited States

Stichwörter der Autor:innen

HIV preventionLong-acting injectable (LAI)PrEP preferencesPrEP stigmaPre-exposure prophylaxis (PrEP)

Substanzen

Anti-HIV AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Duke School of Medicine, Duke University, Durham, NC, USA. aliceschaack@gmail.com.
  • Social Science Research Institute, Duke University, Durham, NC, USA.
  • Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
  • Department of Psychiatry & Behavioral Sciences, Duke University, Durham, NC, USA.
  • Durham VA Health Care System, Durham, NC, USA.
  • Department of Medicine, Division of Infectious Diseases, Duke University, Durham, NC, USA.

Förderung

  • NIAID NIH HHS
  • Center for AIDS Research, Duke University

Zitieren

APA

Schaack, A. K., Allamong, M. B., Hung, F., Barfield, R. T., Wilson, S. M., Watkins, T., Link, K., & McKellar, M. S. (2025). Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users. AIDS and Behavior, 29(10), 3026-3035. https://doi.org/10.1007/s10461-025-04749-0

Vancouver

Schaack AK, Allamong MB, Hung F, Barfield RT, Wilson SM, Watkins T, et al. Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users. AIDS and Behavior. 2025;29(10):3026-3035. doi:10.1007/s10461-025-04749-0

BibTeX
@article{Schaack2025,
  author = {Schaack, Alice K and Allamong, Maxwell B and Hung, Frances and Barfield, Richard T and Wilson, Sarah M and Watkins, Tina and Link, Katherine and McKellar, Mehri S},
  title = {Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users},
  journal = {AIDS and Behavior},
  year = {2025},
  volume = {29},
  number = {10},
  pages = {3026--3035},
  doi = {10.1007/s10461-025-04749-0}
}
Kostenlos starten →